This content was written and submitted by the supplier. It has only been modified to comply with this publication’s space and style.
Schott Pharma prefillable syringes maintain syringe functionality, such as break loose and gliding force and container closure integrity, when used for deep-cold drugs, which are stored and transported on dry ice at temperatures reaching -100°C. The syringes are made of an advanced pharmaceutical-grade polymer and delivered to pharma companies in a standardized nest and tub configuration, ensuring compatibility on major fill-and-finish lines to simplify the filling process.
“While prefillable syringes are typically favored for drug delivery due to their speed and convenience, they were not a viable option for drugs that require storage at -100°C. But now, for the first time, deep-cold medications can be introduced to the market using prefillable polymer syringes,” says Andreas Reisse, CEO at Schott Pharma. “The drug development pipeline for these drugs is extensive, including various therapies such as mRNA, cell, and gene therapies.”
“Our polymer syringes are a favorable choice for deep-cold drugs thanks to the entire platform system, which includes the polymer material, siliconization, the plunger material, and the overall quality management system, among others,” explains Mario Haas, head of business segment drug delivery systems at Schott Pharma. “Based on our track record in the field of mRNA-based applications, we are ready to bring the next deep-cold drugs to the market together with our customers.”